Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Takahisa Maruno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7060-4104; OpenAlex author ID A5027678538. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci206371↗
  2. Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci177533↗
  3. Reduction of butyrate-producing bacteria in the gut microbiome of Japanese patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.09.002↗
  4. Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Co-author DOI 10.1038/s41416-024-02794-5↗
  5. Concomitant occurrence of pancreatic cancer during long-term follow-up for serous neoplasms. Co-author DOI 10.1007/s10396-023-01327-6↗
  6. Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. Co-author DOI 10.1038/s41388-023-02716-4↗
  7. Correction: CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-21-1255↗
  8. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. Co-author DOI 10.7554/elife.55117↗
  9. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2745↗
  10. Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice. Co-author DOI 10.1136/gutjnl-2017-315425↗
  11. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2018.03.039↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroshi Seno · 11 shared papers, 2018–2026 · strength 1.50
  2. Akihisa Fukuda · 8 shared papers, 2018–2026 · strength 1.08
  3. Motoyuki Tsuda · 8 shared papers, 2018–2026 · strength 0.96
  4. Makoto Sono · 5 shared papers, 2023–2026 · strength 0.83
  5. Toshihiko Masui · 4 shared papers, 2023–2026 · strength 0.70
  6. Etsuro Hatano · 4 shared papers, 2023–2026 · strength 0.70
  7. Dieter Saur · 4 shared papers, 2021–2026 · strength 0.64
  8. Satoshi Ogawa · 5 shared papers, 2018–2026 · strength 0.63
  9. Osamu Araki · 4 shared papers, 2018–2026 · strength 0.59
  10. Kei Iimori · 3 shared papers, 2024–2026 · strength 0.56
  11. Munenori Kawai · 3 shared papers, 2024–2026 · strength 0.53
  12. Tsutomu Chiba · 5 shared papers, 2018–2021 · strength 0.43
  13. Tomoaki Matsumori · 3 shared papers, 2020–2023 · strength 0.42
  14. Kozo Ikuta · 4 shared papers, 2018–2024 · strength 0.38
  15. Toshihiro Morita · 3 shared papers, 2020–2024 · strength 0.32
  16. Shinji Üemoto · 3 shared papers, 2018–2021 · strength 0.25
  17. Kyoichi Takaori · 3 shared papers, 2018–2021 · strength 0.25
  18. Kenji Masuo · 2 shared papers, 2019–2023 · strength 0.21
  19. Yoshihiro Nishikawa · 2 shared papers, 2020–2021 · strength 0.18
  20. Yuzo Kodama · 2 shared papers, 2020–2021 · strength 0.18
  21. Kazuyuki Nagai · 1 shared paper, 2024 · strength 0.17
  22. Yoshito Kimura · 2 shared papers, 2018–2019 · strength 0.14
  23. Toshinao Itani · 1 shared paper, 2024 · strength 0.13
  24. Nobuhiro Hieda · 1 shared paper, 2024 · strength 0.13
  25. Kosuke Minaga · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.